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lowed up to review the management of adverse event(s). Results: A total of 226 
radiation related adverse events were found during study period. Among the study 
subjects, majority of them received chemo-radiation (n= 126: 56%) than radiother-
apy (n= 100: 44%) alone. Majority of events observed were Fatigue (n= 39: 17.2%), fol-
lowed by Mucositis (n= 29: 12.8%), Pain (n= 23: 10.17%), Diarrhea (n= 23: 10.17%) and 
Gastritis (n= 22: 9.7%). Less common events were Proctalgia (n= 20:8.8%), Vomiting 
(n= 18: 7.9%), Burning micturition (n= 7: 3%), Dermatitis (n= 7:3%) and Pyrexia (n= 6: 
2.6%). Majority of the vomiting (55%), dehydration (80%), proctalgia (65%), pyrexia 
(67%) and burning micturition (57%) were categorized as grade 1 and grade 2. 
Grade 3 and 4 events were observed as vomiting (17%), diarrhea (13%), fatigue (5%), 
gastritis (4.5%), proctalgia (5%) and mucositis (14%). Most of the grade 3 events or 
grade 4 events were reported in patients who received external radiation therapy 
and was on chemo-radiation therapy compare to who received other types of 
radiation therapy and was on radiation therapy alone. ConClusions: Adverse 
events were found more in patients who received external radiation therapy than 
other types of radiation therapy. Patients on radiation and chemo radiation therapy 
need to be carefully followed up to identify radiation related negative outcomes. 
Appropriate follow up and management of these events reduces patients’ burden 
of cure .
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objeCtives: First-line EGFR-TKIs has become established in EGFR mutation–posi-
tive NSCLC. According to large scale meta-analysis, erlotinib and afatinib showed a 
non-significant difference in efficacy; however, the incidence and severity of EGFR-
TKI–related adverse events (AE) was lower with erlotinib. These safety differences 
may be related to the mechanisms of action (e.g. reversible versus irreversible inhibi-
tion). This study aims to compare the AE costs associated with both drugs, from the 
perspective of the Spanish National Health System (NHS). Methods: The frequency 
of AE was obtained from a recently published meta-analysis using log-linear mixed-
effects models. In Spain, the daily cost of both treatments is the same, therefore, 
only the AE costs were considered. The resources use in the AE management were 
estimated by a Spanish oncologist’s panel and from previous studies conducted 
in Spain. Monte-Carlo simulation was chosen as it allows simulating the effect of 
changes in different parameters obtained from clinical studies and other sources 
to describe real-life distributions. Parameters used in the simulation were the AE 
rates and AE management costs. Results: 1,000 model iterations were generated. 
The AE total cost per patient treated with erlotinib and afatinib was € 657.44 and 
€ 1,272.15, respectively. With erlotinib, the cost per patient due to AE grade ≤ 2 and 
≥ 3 was € 550.86 and € 106.58, respectively, and the cost with afatinib was € 980.63 and 
€ 291.52, respectively too. The reduction in the number of AE with erlotinib could lead 
to average health care costs avoided to the NHS of € 614.71 (95%CI € 324.57; € 881.29) 
per patient. ConClusions: In EGFR mutation-positive NSCLC, first-line erlotinib 
could reduce the health care costs for the Spanish NHS due to the decreased rate 
of AE compared with afatinib. For long-term therapies, avoiding complications and 
reducing costs in the AE management are relevant factors to facilitate the sustain-
ability of health care systems.
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objeCtives: Adverse drug reactions (ADRs) are contributing to poor medication 
adherence, delayed treatment, poor quality of life and increased treatment cost 
in cancer patients. This study was conducted to detect and monitor adverse drug 
reactions (ADRs) through spontaneous reporting and contineous monitoring system 
in patients receiving cancer chemotherapy. Methods: A prospective study was 
conducted at specialty cancer hospital for a period of six months. Clinical pharma-
cists followed the patients admitted to different wards of a study hospital. Medical 
records of the patients were reviewed and patients and their care givers were inter-
viewed to identify ADR. Identified ADRs were discussed with concerned oncologists, 
documented electronically and assessed further. Results: A total of 456 ADRs were 
reported in 378 patients from 410 patients followed during 6 months of period. 
Vomiting (n= 124, 25.87%), blood and bone marrow toxicities (n= 89, 19.51%), con-
stipation (7.8%), alopecia (7%), diarrohea (6.14%), myalgia (4.82%) and peripheral 
neuropathies (4.82%) were common ADRs reported. Anaphylaxis (3.5%), hyperpig-
mentation (3.2%) opportunistic infections (2.63%), muscle cramps (2.4%), hands foot 
syndrome (1.7%), acute renal failure, vasospasm and cardiac toxicities (less than 1%) 
were found less commonly. Cisplatin (27%), Paclitaxel (14.9%), Cyclophosphamide 
(7%), Doxorubicin (4.82%), Fluorouracil (3.9%), Carboplatin (3.28%), Gemcetabine 
(3.07%), Rituximab (1.97%) were drugs found to be associated with ADRs. Most 
(87%) of the ADRs did not lead to cessation of drug but 4% of them needed dosage 
alternation.104 of 124 cases of vomiting were attributed to inappropriate frequency 
and regimen of anti-emetics. 32 of 89 cases of blood injuries were found due to 
lack of preventive care and 16 of 89 cases of blood injuries were suspected due to 
inappropriate dosing. 13 of 16 cases of anaphylaxis were reported due to use of 
specific brand product of Paclitaxel. ConClusions: ADRs due to inappropriate 
frequency, improper dosing and specific formulation can be prevented by imple-
menting quality drug distribution system and strict prescribing and monitoring 
policies.
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objeCtives: The safety and effectiveness of Selective Retina Therapy as a procedure 
that induces the regeneration of the retinal pigmented epithelial cells by selectively 
destroying only the retinal pigmented epithelial cell in patients with retinal diseases 
were assessed. Methods: Assessment was made on the Selective Retina Therapy 
by extending the range of patients to be subjected to this technology by includ-
ing macular edema and central serous chorioretinopathy patients. Intervention 
procedures included a broad range of technologies that selectively damages the 
retinal pigments and all devices without limitation were selected in assessment of 
the safety and effectiveness of this technology. For information search, 8 domestic 
databases including Korea Med and overseas databases including Ovid-Medline, 
Ovid-Embase and Cochrane Library were used. A total of 55 relevant literatures were 
searched through the use of search words related to ‘selective retina therapy’. As 
the result, a total of 7 literatures were included in the final assessment by applying 
the criteria for selection and exclusion to the 28 literatures after having excluded 27 
overlappingly searched literatures. Each of the stages from literature search to appli-
cation of selection standards and extraction of data were carried out independently 
by 2 assessors under the deliberation by the Sub-committee. Results: Although 
there is no safety problem with the Selective Retina Therapy when implemented 
on central serous chorioretinopathy patient, there is no literature that made report 
on the key effectiveness variable of the Therapy,making the assessment of the 
effectiveness of this technology difficulty. ConClusions: Therefore, this technol-
ogy was assessed to be at a stage that requires further researches (Recommendation 
rating of D, Classification as technology in research stage i).
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objeCtives: Biologic therapies are approved for moderate/severe plaque psoria-
sis. In trials of newer biologics, many patients achieved complete skin clearance. 
This abstract reports interim Resultsfrom a study examining real-world effective-
ness of biologics in psoriasis. Methods: This prospective observational study 
includes adults initiating biologic treatment, or switching to a new biologic, for 
psoriasis in Europe and the US. Dermatologist evaluation of the Psoriasis Area and 
Severity Index (PASI) and the patient-reported Psoriasis Symptom Index (PSI] and 
Dermatology Life Quality Index (DLQI) are collected at baseline, 6 and 12 months 
after biologic initiation. Endpoints include complete skin clearance (100% improve-
ment in PASI [PASI 100] or PASI= 0), PASI 90, PASI 75, PSI and DLQI. Missing data are 
imputed using the last observation carried-forward. These interim Resultsinclude 
patients who had the opportunity to complete a 6-month assessment. Results: 
This interim analysis included 126 patients (69.8% male, mean [SD] age 47.3 [14.3] 
years, mean [SD] psoriasis duration 17.3 [12.9] years). At baseline, mean (SD) PASI 
was 14.8 (9.4), and 53.2% patients were biologic-naïve. At 6-months, 17.5% [95% 
CI: 11.3%, 25.2%] of patients achieved complete skin clearance; fewer than half 
(48.0% [39.0%, 57.1%]) achieved a PASI 75, 28.0% [20.3%, 36.7%] achieved a PASI 90, 
and 17.6% [11.4%, 25.4%] a PASI 100. In addition, 16.8% of patients had a PSI of 0 
and 23.8% a DLQI of 0 (lower scores indicate fewer psoriasis symptoms and better 
quality of life). ConClusions: Fewer than 20% of patients achieved complete 
skin clearance 6 months after initiating a biologic and less than half achieved a 
75% improvement in PASI. In addition, more than 75% of patients reported some 
decrement to quality of life and more than 80% reported psoriasis symptoms. 
These Resultssuggest that more effective treatments could improve outcomes 
for many patients with moderate to severe psoriasis.
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objeCtives: This study was conducted to assess the pattern of radiation related 
adverse events and its management in patients who are on radiation therapy or 
chemo-radiation therapy. Methods: This was a prospective observational study 
conducted for a period of six months. Patients on radiation therapy or chemo-radi-
ation therapy were enrolled and followed by clinical pharmacists on daily basis to 
identify adverse event(s) if any. Upon identification, adverse events were discussed 
with concerned radiation oncologists for authentication and graded as per defined 
by Radiation Therapy Oncology Group (RTOG). Enrolled patients were further fol-
